Encyclopedia entry

KPV (Lysine-Proline-Valine)

Evidence: Mechanistic

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-05-26

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

AI-friendly summary · KPV

KPV is a synthetic tripeptide composed of lysine, proline, and valine, corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical literature, mostly in-vitro and early rodent models of colitis and wound healing, proposes anti-inflammatory effects via the melanocortin signalling pathway. No phase II or phase III human clinical trials have been published. PeptideClear is gathering UK retailer data for KPV; commercial coverage is not yet live.

Mechanism of action

How KPV works

KPV is proposed to act on the melanocortin signalling system as a short, stable fragment of alpha-MSH. In cell-culture and rodent inflammatory-bowel-disease models it has been reported to dampen NF-kB activation and reduce production of pro-inflammatory cytokines such as IL-6 and TNF-alpha at intestinal epithelial cells. The relevant melanocortin receptor subtype in humans is not definitively established, and most authors describe the mechanism as anti-inflammatory rather than receptor-specific.

Source: PubMed search: KPV peptide (preclinical IBD and wound-healing literature)

What the literature shows (preclinical only)

The KPV literature is small relative to better-known research peptides. The bulk of published work is in-vitro on cultured intestinal epithelial cells, or early rodent models of induced colitis (commonly DSS-induced or TNBS-induced colitis in mice). A separate strand covers wound-healing in cell-culture and rodent skin models. Independent replication across laboratories exists but the human dataset is empty.

· In-vitro reduction of NF-kB activation and pro-inflammatory cytokine output in cultured intestinal epithelial cell lines.
· Rodent DSS-induced and TNBS-induced colitis models reporting reduced histological inflammation scores in KPV-treated animals.
· Cell-culture and rodent skin wound-healing models reporting accelerated re-epithelialisation in KPV-exposed tissue.
· Mechanistic discussion linking KPV to the melanocortin pathway via its alpha-MSH C-terminal origin.
· No published phase II or phase III human randomised controlled trials. The clinical evidence base is effectively empty.

Related compound: BPC-157 (see BPC-157 encyclopedia entry) sits adjacent in the gut-research preclinical literature, with a different proposed mechanism and a larger but similarly preclinical evidence base.

UK regulatory status

KPV sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It has zero UK marketing authorisations as a medicine. UK retailers can sell it lawfully only by labelling it for "research use only, not for human or animal consumption" and by avoiding any therapeutic claim.

· Not a controlled drug under the Misuse of Drugs Act 1971.
· Not scheduled under the Psychoactive Substances Act 2016.
· No UK marketing authorisation as a medicine.
· No EMA marketing authorisation in the EU.
· Sold legally as a research chemical when marketed without health claims.
· Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Risks and unknowns

What the literature does not yet show about KPV

Known concerns

No published human RCT data on safety profile or long-term tolerability.
Preclinical literature base is small relative to better-studied research peptides; reproducibility across independent groups is partial rather than well-established.
Purity of UK research-peptide supply varies. CoA gating and HPLC analysis differ between retailers.
Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.

Open questions in the literature

Optimal route of administration in humans has never been formally studied.
Pharmacokinetics in humans (half-life, clearance, oral vs subcutaneous bioavailability) are not characterised.
The precise melanocortin receptor subtype responsible for the proposed anti-inflammatory effect in humans is not definitively established.
Long-term effects beyond the short duration of typical rodent colitis studies are unknown.

Regulatory note

Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Where to learn more

· PubMed search: KPV peptide returns the preclinical IBD and wound-healing literature.
· PubMed: KPV colitis for the rodent DSS-induced and TNBS-induced colitis model papers.
· PubMed: alpha-MSH KPV for the mechanistic alpha-MSH fragment context.
· Related compound: BPC-157 encyclopedia entry for adjacent gut-research preclinical work.
· UK retailer purity comparison: research peptides UK retailers.

Frequently asked questions

Is KPV legal in the UK?

KPV is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is sold legally by UK research peptide retailers under "research use only, not for human or animal consumption" framing. It holds no UK marketing authorisation as a medicine.

What does the human evidence show for KPV?

No phase II or phase III randomised human clinical trials on KPV have been published. The literature base is limited to in-vitro cell-culture work and early rodent models of colitis and wound healing. There is no human efficacy or safety dataset that would meet MHRA, EMA, or FDA submission standards.

What is the regulatory status of KPV in the UK?

KPV has no UK marketing authorisation as a medicine. It is sold as a research chemical when marketed without health claims. The moment a retailer, clinic, or commentator makes a therapeutic claim about KPV it becomes an unlicensed medicinal product and the MHRA can act.

How does KPV relate to alpha-MSH?

KPV is the C-terminal tripeptide fragment (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical work proposes that this short fragment retains the anti-inflammatory melanocortin signalling of the parent hormone while losing the pigmentation effects. The proposal is mechanistic and has not been validated in human trials.

Where can I learn more about KPV?

A PubMed search for "KPV peptide" returns a small literature base, primarily preclinical, covering cell-culture inflammation models and rodent colitis studies. The "Where to learn more" section above links to the primary sources.

UK retailer coverage

PeptideClear is gathering UK retailer data for KPV. Commercial price comparison and retailer table not yet live for this compound. In the meantime, the UK research peptide retailer directory covers the broader supply landscape.

UK research peptide retailers

Clinical evidence record

Read the clinical evidence record for KPV

Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.

Popular on PeptideClear

Research peptides

BPC-157 (UK)

Collagen

Best UK collagen brands 2026

GLP-1

UK GLP-1 clinics compared

Methodology

CoA Trust Index

Shop

BPC-157 UK prices

Ready to buy

Buy KPV in the UK

UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.

Compare UK retailers CoA Trust Index